Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05198596
Recruitment Status : Not yet recruiting
First Posted : January 20, 2022
Last Update Posted : June 13, 2022
Sponsor:
Information provided by (Responsible Party):
Medigen Vaccine Biologics Corp.

Brief Summary:
The purpose of this study is to assess the immunogenicity and safety of MVC- COV1901 vaccine compared to AZD1222 in heathy adults.

Condition or disease Intervention/treatment Phase
COVID-19 Vaccine Biological: MVC-COV1901 Biological: AZD1222 Phase 3

Detailed Description:
The primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titres in adult participants so as to demonstrate immunogenic superiority of MVC-COV1901 to the active control, AZD1222 vaccine, in terms of the GMT of neutralizing antibodies at 14 days after the second dose of the study intervention. This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity in terms of antigen-specific immunoglobulin as well as the potential efficacy of MVC-COV1901 in preventing COVID-19.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Phase III, Parallel Group, Prospective, Randomized, Double-blind, Active-controlled, Two-arm, Multi-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of MVC-COV1901 Compared to AZD1222 in Adult of 18 Years and Above
Estimated Study Start Date : July 2022
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

Drug Information available for: AZD-1222

Arm Intervention/treatment
Experimental: MVC-COV1901
S-2P protein with CpG and Aluminum Hydroxide/0.5mL
Biological: MVC-COV1901
Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Active Comparator: AZD1222
ChAdOx1 nCoV-19 vaccine
Biological: AZD1222
Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region




Primary Outcome Measures :
  1. Immunogenicity of neutralizing antibody (GMT) [ Time Frame: Day 1 to Day 43 ]

    To demonstrate the immunogenic superiority of MVC-COV1901 to AZD1222 in terms of neutralizing antibody titers at 14 days after the second vaccination

    -GMT ratio


  2. Incidence of Adverse Event within 28 days post the second study intervention [ Time Frame: Day 1 to Day 57 ]

    To evaluate the safety and tolerability of MVC-COV1901 compared to AZD1222 from Day 1 to 28 days after the second vaccination

    The number and percentage of participants with the occurrence of:

    • Solicited local AEs
    • Solicited systemic AEs
    • Unsolicited AEs
    • Medically attended AEs (MAAEs) • AESIs
    • VAED
    • SAEs


Secondary Outcome Measures :
  1. Immunogenicity of neutralizing antibody (GMT) [ Time Frame: Day 29 to Day 209 ]

    To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209

    • GMT


  2. Immunogenicity of neutralizing antibody(SCR) [ Time Frame: Day 29 to Day 209 ]

    To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209

    • SCR


  3. Immunogenicity of neutralizing antibody(GMT ratio) [ Time Frame: Day 29 to Day 209 ]

    To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209

    • GMT ratio


  4. Incidence of Adverse Event throughout study conduct [ Time Frame: Day 1 to Day 209 ]

    To evaluate the safety of MVC COV1901 compared to AZD1222 over the study period

    The number and percentage of participants with the occurrence of:

    • MAAEs
    • AESIs
    • VAED
    • SAEs


Other Outcome Measures:
  1. Incidence of confirmed COVID-19 cases [ Time Frame: Day 15 to Day 209 ]

    To estimate the efficacy of MVC-COV1901, as compared to AZD1222, in the prevention of COVID-19 in terms of :

    • The number of laboratory-confirmed COVID-19 cases occurring ≥ 15 days after any dose of study intervention.
    • The number of laboratory-confirmed COVID-19 severe cases occurring ≥ 15 days after any dose of study intervention.

  2. Immunogenicity of antigen-specific immunoglobulin titers(GMT) [ Time Frame: Day 29 to Day 209 ]

    To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209

    • GMT


  3. Immunogenicity of antigen-specific immunoglobulin titers(SCR) [ Time Frame: Day 29 to Day 209 ]

    o evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209

    • SCR


  4. Immunogenicity of antigen-specific immunoglobulin titers(GMT ratio) [ Time Frame: Day 29 to Day 209 ]

    To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209

    • GMT ratio


  5. Cell Mediated Immunity [ Time Frame: Day 1 to Day 43 ]
    To assess cell-mediated immune response of MVC-COV1901compared to AZD1222



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female participant aged 18 years and above at randomization.
  2. Healthy adult or adult with pre-existing medical conditions who is in a stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study.
  3. Female participant:

    1. A female participant is eligible if the participant is a woman of non-childbearing potential, i.e., surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.
    2. If the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. Highly effective methods of contraception include:

    i. Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine hormonal-releasing system ii. Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository iii. Azoospermic partner (vasectomized or due to medical cause), provided the partner is the sole sexual partner of the female participant and the absence of sperm has been confirmed (from medical records/examination/history).

    c.Have a negative pregnancy test

  4. Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
  5. Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.

Exclusion Criteria:

  1. Pregnant or breastfeeding or have plan to become pregnant within 30 days after the last administration of the study intervention.
  2. Employees at the investigator's site, of the Sponsor or delegate (e.g., contract research organization) who are directly involved in the conduct of the study.
  3. Currently receiving or received any investigational intervention within 30 days prior to the first dose of the study intervention.
  4. Administered any licensed live-attenuated vaccines within 28 days or other licensed non- live-attenuated vaccines within 7 days prior to the first dose of the study intervention.
  5. Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of the study intervention.
  6. Currently receiving or anticipate receiving concomitant immunosuppressive or immune- modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of the study intervention.
  7. Currently receiving or anticipate receiving treatment with tumor necrosis factor (TNF)-α inhibitors, e.g., infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of the study intervention.
  8. Major surgery or any radiation therapy within 12 weeks prior to the first dose of the study intervention.
  9. Has received any other investigational or approved COVID-19 vaccine.
  10. Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
  11. A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
  12. Bleeding disorder considered a contraindication to intramuscular (IM) injection or phlebotomy.
  13. Documented SARS-CoV-2 infection prior to the first dose of study intervention, or an individual with positive anti-SARS-CoV-2 antibody test at screening (including rapid tests).
  14. A history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia, thrombosis with thrombocytopenia syndrome (TTS), antiphospholipid syndrome, or capillary leak syndrome.
  15. Participant who, in the investigator's judgement, is not in a stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include a participant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.
  16. A history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901 or AZD1222.
  17. Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05198596


Contacts
Layout table for location contacts
Contact: Criss Cheng +886277450830 p 606 crisscheng@medigenvac.com
Contact: Howard Cheng +886277450830 p 601 howardcheng@medigenvac.com

Locations
Layout table for location information
Thailand
Uthumpornphisai Hospital
Sisaket, Thailand
Contact: Pavarit Arayasukawat, MD         
Sponsors and Collaborators
Medigen Vaccine Biologics Corp.
Investigators
Layout table for investigator information
Study Director: Allen Lien, MD. Dr.PH Medigen Vaccine Biologics
Layout table for additonal information
Responsible Party: Medigen Vaccine Biologics Corp.
ClinicalTrials.gov Identifier: NCT05198596    
Other Study ID Numbers: CT-COV-32
First Posted: January 20, 2022    Key Record Dates
Last Update Posted: June 13, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medigen Vaccine Biologics Corp.:
COVID-19 Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases